Caris Life Sciences Inc CAI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Caris Life Sciences Launches New National Commercial Featuring Jordan Spieth Highlighting the Power of Artificial Intelligence in Early Stage Cancer Detection
-
Caris Life Sciences to Report Third Quarter 2026 Financial Results on November 4, 2026
-
Caris Life Sciences to Present Eight Studies Highlighting the Power of AI, Multi-Omics and Precision Medicine at ESMO 2026
-
This test screens for 50 cancers - but whether Medicare and other health insurers will cover it hinges on FDA approval
-
Caris Life Sciences Launches New National Commercial Featuring Kevin Costner to Raise Awareness of Early Cancer Detection and Caris Detect
-
Caris Life Sciences to Present New Research Advancing Precision Oncology at the IASLC 2026 World Conference on Lung Cancer
-
Caris Life Sciences Publishes npj Precision Oncology Study Showing AI-Guided Therapy Selection is Predictive of Longer Survival in Patients with Pancreatic Cancer
-
Caris Life Sciences Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
Trading Information
- Previous Close Price
- $33.67
- Day Range
- $33.50–35.43
- 52-Week Range
- $14.20–35.43
- Bid/Ask
- $35.15 / $35.39
- Shares Outstanding
- 282.60M
- Market Cap
- $10.00B
- Volume/Avg
- 318,162 / 5M
Key Statistics
- Price/Earnings (Normalized)
- 74.49
- Price/Sales
- 9.64
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- 0.23%
Company Profile
Caris Life Sciences Inc is a patient-centric, next-generation AI TechBio company. It develop and commercialize solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 1,846
Valuation
|
Metric
|
CAI
|
|---|---|
Price/Earnings (Normalized) | 74.49 |
Price/Book Value | 16.08 |
Price/Sales | 9.64 |
Price/Cash Flow | 41.19 |
Price/Earnings
CAI
Financial Strength
|
Metric
|
CAI
|
|---|---|
Quick Ratio | 4.75 |
Current Ratio | 5.53 |
Interest Coverage | 2.64 |
Quick Ratio
CAI
Profitability
|
Metric
|
CAI
|
|---|---|
Return on Assets (Normalized) | 16.46% |
Return on Equity (Normalized) | 33.36% |
Return on Invested Capital (Normalized) | 20.06% |
Return on Assets
CAI
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|^My>n%w | LOCK|DB#> | $132B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|@jzzGD | LOCK|>!B<& | $84B | |||
| Moderna Inc
MRNA
| LOCK|Y^W$&L | LOCK|@g@ | $83B | |||
| argenx SE ADR
ARGX
| LOCK|Bs?JG>Y | LOCK|Gr> | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|$>pQB^$ | LOCK|sZs | $42B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|<#^$p&C | LOCK|tVQDk | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|T$!$^Q># | LOCK|ZLg%K | $29B | |||
| Incyte Corp
INCY
| LOCK|GB$$?? | LOCK|$m! | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|BfpqXp | LOCK|#M | $22B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|DN>@<v | LOCK|X@G | $14B |
United States